COVID-19 and Its Impact on Persons with Mental Illness and Substance Use

The COVID-19 pandemic has brought significant challenges to both healthcare systems and public health. Social distancing, disruption of healthcare services,…

Emerging Data on Novel Psychoactive Substances and Clinical Effects

Emerging Data on Novel Psychoactive Substances and Clinical Effects Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive…

Designer Opioids and Benzodiazepines

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs which vary significantly…

Synthetic Cannabinoids and Synthetic Stimulants

Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs; however, they…

Expansion of Oral Fluid Testing of Behavioral Health Drugs

Aegis’ oral fluid testing menu has been expanded to allow providers the option to test for many additional medications and/or illicit drugs. The enhancement…

Review of New InterAct Rx Analyte Positivity

In 2015, Aegis Sciences Corporation began to seek out a way to expand the clinical information that could be provided through definitive testing.  With…

Broaden your Understanding: Benefits of the InterACT Rx™ Expansion

In 2015, Aegis Sciences Corporation began to seek out a way to expand the clinical information that could be provided through definitive testing.  With…